AMONAFIDE IN PATIENTS WITH LEIOMYOSARCOMA OF THE UTERUS - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP STUDY

Twenty-six evaluatable patients who had leiomyosarcoma of the uterus w ere treated with amonafide, 300 mg/m(2), for 5 consecutive days every 3 weeks. One partial response (4%) resulted. Hematologic toxicity was substantial, with grade 3 or 4 events occurring as follows: leukopenia , 12 patients (46%); thrombocytopenia, 4 patients (15%); and granulocy topenia, 7 patients (27%). One patient had transient grade 4 renal fai lure. Considering the poor activity and substantial toxicity that was observed, no further studies are planned by the Gynecologic Oncology G roup using amonafide at this dose schedule in leiomyosarcomas.